Alexion, Procter revise pexelizumab deal

ALXN and PG revised their 1999 deal under which PG received exclusive worldwide development and marketing rights to ALXN's pexelizumab (5G1.1-SC) C5 complement inhibitor. As revised, ALXN will partici...